Tessa Therapeutics Ltd. has a closed a $126 million series A financing round to advance its ongoing clinical development, which includes the initiation of a pivotal trial of autologous CD30-CAR-T therapy (TT-11) and advancement of allogeneic CD30.CAR EBVST therapy (TT-11X) programs.

A tightening of rules for biotech listings on the Shanghai STAR Market may have contributed to a visible cool-down in biotech IPOs, with fewer listings in Chinese stock markets in the first half of 2022.

Meta Pharmaceuticals Inc. has raised $15 million in seed and pre-series A rounds in six months for the pipeline and AI platform development. Shenzhen, China-based Meta Pharma plans to use the new funds to support its three candidates to enter clinical trials, as well as the development of its Meta-map platform for pipeline expansion.

AI-enabled drug discovery company Insilico Medicine Ltd. has raised $60 million in a series D round to support expansion of its pipeline.

Rznomics Inc. recently secured ₩37.2 billion (US$30 million) from private investors and the Korean government in a series C financing round.

Abliva AB has gone above its market capitalization to raise the money it needs to start a phase II/III trial of KL-1333 for the treatment of primary mitochondrial disease.